Analysis of CD34-positive cells in bone marrow from patients with myelodysplastic syndromes and acute myeloid leukemia and in normal individuals: A comparison between FACS analysis and immunohistochemistry

European Journal of Haematology

Volumn 56, Issue 3, 1996, Pages 124-129

  Kanter Lewensohn, Lena ^a   Hellström Lindberg, Eva ^a   Kock, Yvonne ^a   Elmhorn Rosenborg, Annika ^a   Öst, Ake ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Acute leukemia; CD34; Myelodysplastic syndromes

Indexed keywords

CD34 ANTIGEN;

ACUTE GRANULOCYTIC LEUKEMIA; AGED; ARTICLE; BONE MARROW CELL; CLINICAL ARTICLE; CONTROLLED STUDY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MYELODYSPLASTIC SYNDROME; PRIORITY JOURNAL;

ACUTE DISEASE; ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD34; BACTERIAL PROTEINS; BIOTIN; BONE MARROW; FALSE POSITIVE REACTIONS; FLOW CYTOMETRY; FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT; HEMATOPOIETIC STEM CELLS; HUMANS; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; LEUKEMIA, MYELOID; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; PARAFFIN EMBEDDING; PROGNOSIS; STREPTAVIDIN;

EID: 0029980305     PISSN: 09024441     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-0609.1996.tb01330.x     Document Type: Article

References (23)

1. BENNETT JM, CATOVSKY D, DANIEL MT, et al. The French-American-British (FAB) Co-operative Group. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 1982: 51: 189-199.
2. KERKHOFS H, HERMANS J, HAAK HL, LEEKSMA CHW. Utility of the FAB classification for myelodysplastic syndromes: Investigation of prognostic factors in 237 patients. Br J Haematol 1987: 65: 73-81.
3. MUFTI GJ, STEVENS JR, OSCIER DG, HAMBLIN TJ, MACHIN D. Myelodysplastic syndromes: a scoring system with prognostic significance. Br J Haematol 1985: 59: 425-433.
4. SANZ GF, SANZ MA, VALLESPI T, et al. Two regression models and a scoring system for predicting survival and planning treatment in myelodysplastic syndromes: a multivariate analysis of prognostic factors in 370 patients. Blood 1989: 74: 395-408.
5. MOREL P, HEBBAR M, LAI JL, et al. Cytogenetic analysis has strong independent prognostic value in de novo myelodysplastic syndromes and can be incorporated in a new scoring system: a report on 408 cases. Leukemia 1993: 7: 1315-1323.
6. LAMBERTENGHI-DELILIERS G, ORAZI A, LUKSCH R, ANNALORO C, SOLIGO D. Myelodysplastic syndrome with increased marrow fibrosis: a distinct clinico-pathological entity. Br J Haematol 1991: 78: 161-166.
7. TRICOT G, WOLF-PETERS C DE, VLIETINCK R, VERWILGHEN RL. Bone marrow histology in myelodysplastic syndromes. II. Prognostic value of abnormal localization of immature precursors in MDS. Br J Haematol 1984: 58: 217-225.
8. CIVIN CI, STRAUSS LC, BROVALL C, FACKLER MJ, SCHWARTZ JF, SHAPER JH. Antigenic analysis of hematopoiesis. III. A hematopoietic progenitor cell surface antigen defined by a monoclonal antibody raised against KG-1a cells. J Immunol 1984: 133: 157-165.
9. + cells in normal and pathological bone marrow biopsies by QBEND10 monoclonal antibody. Leukemia 1991: 5: 1026-1030.
10. VAUGHAN WP, CIVIN CI, WEISENBURGER DD, et al. Acute leukemia expressing the normal human hematopoietic stem cell membrane glycoprotein CR 34 (My 10). Leukemia 1988: 2: 661-666.
11. BOROWITZ MJ, GOCKERMAN JP, MOORE JO, et al. Clinicopathologic and cytogenetic features of CD 34 (My 10) positive acute nonlymphocytic leukemia. AJCP 1989: 91: 265-270.
12. CAMPOS L, GUYOTAT D, ARCHIMBAUD E, et al. Surface marker expression in adult acute myeloid leukemias: correlation with initial characteristics, morphology and response to therapy. Br J Haematol 1989: 72: 161-166.
13. GELLER RB, ZAHURAK M, HURWITZ CA, BURKE PJ, KARP JE. Prognostic importance of immunophenotyping in adults with acute myelocytic leukaemia: the significance of the stem-cell glycoprotein CD 34 (My 10). Br J Haematol 1990: 76: 340-347.
14. - phenotypes with shorter survival. Leukemia 1992: 6: 393-399.
15. BRADSTOCK K, MATTHEWS J, BENSON E, et al. and the Australian Leukemia Group. Prognostic value of immunophenotyping in acute myeloid leukemia. Blood 1994: 84: 1220-1225.
16. SOLIGO DA, ORIANI A, ANNALORO C, et al. CD34 immunohistochemistry of bone marrow biopsies: prognostic significance in primary myelodysplastic syndromes. Am J Hematol 1994: 46: 9-17.
17. + cells: an adverse prognostic factor in the myelodysplastic syndromes. Am J Hematol 1992: 39: 96-101.
18. ORAZI A, CATTORETTI G, SOLIGO D, LUKSCH R, LAMBERTENGHI DELILIERS G. Therapy-related myelodysplastic syndromes: FAB classification, bone marrow histology and immunohistology in the prognostic assessment. Leukemia 1993: 7: 838-847.
19. GUYOTAT D, CAMPOS L, THOMAS X, et al. Myelodysplastic syndromes: a study of surface markers and in vitro growth patterns. Am J Hematol 1990: 34: 26-31.
20. CORDELL JL, FALINI B, ERBER WE, et al. Immunoenzymatic labeling of monoclonal antibodies using immune complexes of alkaline phosphatase and monoclonal anti-alkaline phosphatase (APAAP complexes).
21. MACIEJEWSKI JP, ANDERSON S, KATEVAS P, YOUNG NS. Phenotypic and functional analysis of bone marrow progenitor cell compartment in bone marrow failure. Br J Haematol 1994: 87: 227-234.
22. SIENA S, BREGNI M, RAVAGNANI F, et al. Heterogeneity of circulating hematopoietic progenitors in cancer patients treated with high-dose cyclophosphamide and recombinant human granulocyte macrophage colony stimulating factor (RHGM-CSF). Haematologica 1990: 75: Suppl 1: 6-10.
23. LIST A, SPIER CM, CLINE A, DOLL DC, GAREWAL H. Expression of the multidrug resistance gene product (P-glycoprotein) in myelodysplasia is associated with a stem cell phenotype. Br J Haematol 1991: 78: 28-34.